223 related articles for article (PubMed ID: 20303261)
21. Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
Li X; Wu C; Lin X; Cai X; Liu L; Luo G; You Q; Xiang H
Eur J Med Chem; 2019 Jan; 161():445-455. PubMed ID: 30384047
[TBL] [Abstract][Full Text] [Related]
22. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Allen E; Walters IB; Hanahan D
Clin Cancer Res; 2011 Aug; 17(16):5299-310. PubMed ID: 21622725
[TBL] [Abstract][Full Text] [Related]
23. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
El-Khoueiry A; Posey JA; Castillo Ferrando JR; Krishnamurthi SS; Syed S; Kollia G; Walters I; Fischer BS; Masson E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):53-64. PubMed ID: 23719718
[TBL] [Abstract][Full Text] [Related]
24. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.
Liu H; Lee ES; Gajdos C; Pearce ST; Chen B; Osipo C; Loweth J; McKian K; De Los Reyes A; Wing L; Jordan VC
J Natl Cancer Inst; 2003 Nov; 95(21):1586-97. PubMed ID: 14600091
[TBL] [Abstract][Full Text] [Related]
25. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
Patel JB; Mehta J; Belosay A; Sabnis G; Khandelwal A; Brodie AM; Soprano DR; Njar VC
Br J Cancer; 2007 Apr; 96(8):1204-15. PubMed ID: 17387344
[TBL] [Abstract][Full Text] [Related]
26. Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.
LoRusso P; Shapiro GI; Hurwitz H; Pilat MJ; Chemidlin J; Kollia G; Syed S; Fischer B; Masson E
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1377-85. PubMed ID: 21461891
[TBL] [Abstract][Full Text] [Related]
27. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice.
O'Regan RM; Gajdos C; Dardes RC; De Los Reyes A; Park W; Rademaker AW; Jordan VC
J Natl Cancer Inst; 2002 Feb; 94(4):274-83. PubMed ID: 11854389
[TBL] [Abstract][Full Text] [Related]
28. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249
[TBL] [Abstract][Full Text] [Related]
29. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
30. A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate.
Scandlyn MJ; Stuart EC; Somers-Edgar TJ; Menzies AR; Rosengren RJ
Br J Cancer; 2008 Oct; 99(7):1056-63. PubMed ID: 18797454
[TBL] [Abstract][Full Text] [Related]
31. The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.
Johnston SR; Riddler S; Haynes BP; A'Hern R; Smith IE; Jarman M; Dowsett M
Br J Cancer; 1997; 75(6):804-9. PubMed ID: 9062399
[TBL] [Abstract][Full Text] [Related]
32. Development and characterization of a tamoxifen-resistant breast carcinoma xenograft.
Naundorf H; Becker M; Lykkesfeldt AE; Elbe B; Neumann C; Büttner B; Fichtner I
Br J Cancer; 2000 Jun; 82(11):1844-50. PubMed ID: 10839300
[TBL] [Abstract][Full Text] [Related]
33. Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis.
Li Z; Carrier L; Belame A; Thiyagarajah A; Salvo VA; Burow ME; Rowan BG
Breast Cancer Res Treat; 2009 Nov; 118(1):33-43. PubMed ID: 18855134
[TBL] [Abstract][Full Text] [Related]
34. Brivanib alaninate inhibited dengue virus proliferation through VEGFR2/AMPK pathway.
Wan Y; Wu W; Wan Y; Li L; Zhang J; Chen X; Liu S; Yao X
Pharmacol Res; 2021 Aug; 170():105721. PubMed ID: 34116207
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice.
Conley BA; Ramsland TS; Sentz DL; Wu S; Rosen DM; Wollman M; Eiseman JL
Cancer Chemother Pharmacol; 1999; 43(3):183-97. PubMed ID: 9923548
[TBL] [Abstract][Full Text] [Related]
36. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
[TBL] [Abstract][Full Text] [Related]
37. Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report.
Zhu H; Zhang C; Yang X; Yi C
Medicine (Baltimore); 2019 Mar; 98(10):e14823. PubMed ID: 30855507
[TBL] [Abstract][Full Text] [Related]
38. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Nutr Cancer; 2007; 58(2):162-70. PubMed ID: 17640162
[TBL] [Abstract][Full Text] [Related]
39. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
[TBL] [Abstract][Full Text] [Related]
40. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
